180 Life Sciences Corp.
ATNF
$1.04
-$0.01-0.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -121.48% | -248.26% | 91.85% | 100.32% | 77.54% |
| Total Depreciation and Amortization | -- | -113.66% | -57.49% | -16.08% | 8.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 144.44% | 441.79% | -100.28% | -125.13% | -53.12% |
| Change in Net Operating Assets | 519.64% | 134.56% | -43.48% | 39,447.62% | -161.02% |
| Cash from Operations | 17.39% | 55.99% | 87.40% | 123.33% | 73.30% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 98.75% | -20.35% | -84.82% | -2.79% | 43.61% |
| Issuance of Common Stock | -- | 546.22% | -100.00% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 98.75% | 243.44% | -119.46% | -110.76% | 43.72% |
| Foreign Exchange rate Adjustments | -80.00% | 5,977.55% | -1,321.47% | -52.94% | -112.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.79% | 739.32% | -245.50% | 173.76% | 69.94% |